现代化临床试验入组标准:ASCO-FOCR HIV工作组建议
ASCO-Friends of Cancer Research HIV工作组通过电话会议、回顾46份新药申请及NCI资助研究的HIV相关入组标准,并于2016年多利益相关方研讨会讨论,提出针对HIV感染者的临床试验入组标准建议,聚焦药理学与免疫学考量,平衡患者安全、研究药物可及性与研究完整性。
要点
- HIV感染本身不应再作为大多数研究的排除标准。
- HIV相关入组标准应针对合并抗逆转录病毒治疗和免疫状态,并适合特定癌症。
- 扩大入组以更多纳入HIV患者在多情况下是合理的,可能加速有效疗法的开发。
核心结论
- 在大多数情况下,扩大临床试验入组以更多纳入HIV感染者是合理的,可能加速这一未满足临床需求领域有效疗法的开发。
研究设计与样本
- HIV工作组于2016年1月至4月开展系列电话会议,回顾2011至2015年FDA首次批准用于成人癌症的独特药物的46份新药申请注册研究,并回顾NCI资助研究的HIV相关入组标准,结果于2016年5月12日多利益相关方研讨会讨论完善。
主要发现
- 在大多数新型抗癌药物研究中,排除HIV患者仍然常见。
- NCI资助研究中HIV相关入组标准的模型具有指导意义。
- HIV感染本身不应再作为大多数研究的排除标准。
关键数值与推荐
- HIV相关入组标准应涉及合并抗逆转录病毒治疗和免疫状态,并以适合特定癌症的方式设计。
临床怎么用
- 在大多数研究中不再将HIV感染本身作为排除标准。
- 针对HIV感染者的入组标准应结合抗逆转录病毒治疗和免疫状态,并依据特定癌症类型设计。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose People with HIV are living longer as a result of effective antiretroviral therapy. Cancer has become a leading cause of morbidity and mortality in this patient population. However, studies of novel cancer therapeutics have historically excluded patients with HIV. Critical review of eligibility criteria related to HIV is required to accelerate development of and access to effective therapeutics for HIV-infected patients with cancer and make studies more generalizable to this patient population. Methods From January through April 2016, the HIV Working Group conducted a series of teleconferences; a review of 46 New Drug Applications from registration studies of unique agents studied in adults with cancer that led to the initial US Food and Drug Administration approval of that agent from 2011 to 2015; and a review of HIV-related eligibility criteria from National Cancer Institute-sponsored studies. Results were discussed and refined at a multistakeholder workshop held May 12, 2016. The HIV Working Group developed recommendations for eligibility criteria that focus on pharmacologic and immunologic considerations in this patient population and that balance patient safety, access to appropriate investigational agents, and study integrity. Results Exclusion of patients with HIV remains common in most studies of novel cancer agents. Models for HIV-related eligibility criteria in National Cancer Institute-sponsored studies are instructive. HIV infection itself should no longer be an exclusion criterion for most studies. Eligibility criteria related to HIV infection that address concurrent antiretroviral therapy and immune status should be designed in a manner that is appropriate for a given cancer. Conclusion Expanding clinical trial eligibility to be more inclusive of patients with HIV is justified in most cases and may accelerate the development of effective therapies in this area of unmet clinical need.
引用
- Uldrick TS, Ison G, Rudek MA, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol. 2017. PMID: 28968173. doi:10.1200/JCO.2017.73.7338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。